Literature DB >> 20827165

Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study.

Melchor Riera1, Antoni Payeras, Maria A Marcos, Diego Viasus, Maria C Farinas, Ferran Segura, Julian Torre-Cisneros, Alejandro Martín-Quirós, Jesús Rodríguez-Baño, Juan Vila, Elisa Cordero, Jordi Carratalà.   

Abstract

OBJECTIVE: The aim of the study was to describe the clinical presentation and prognosis in HIV-1-infected patients with hospital admission and pandemic influenza A 2009 (H1N1) confirmed, and compare this data with those of a general population.
DESIGN: : This is a prospective study in nature.
METHODS: All adult patients admitted to 13 hospitals in Spain with confirmed influenza A 2009(H1N1) virus infection by real-time reverse transcriptase PCR assay or culture from June 12 to November 10, 2009 were recruited and followed up until 1 month after discharge. In the HIV group risk factors for HIV infection, AIDS criteria, last CD4 cell count and viral load, and antiretroviral therapy and pneumococcal vaccines were collected.
RESULTS: Five hundred and eighty-five patients were recruited, 26 with HIV-1 infection and 559 non-HIV. The HIV patients had a long-term well controlled infection with a median CD4 cell count 503 cells/μl and 84% with undetectable viral load, although more frequently they had chronic liver and chronic obstructive pulmonary disease. No significant differences were observed about reported symptoms and physical findings on hospital admission. About 50% of patients in both groups present radiological infiltrates and 30% present respiratory failures. Practically all the patients in both groups received influenza antiviral therapy and in each group 80% received antibacterial therapy. No differences were observed in clinical outcomes.
CONCLUSION: In HIV patients, well controlled on HAART, the pandemic influenza virus AH1N1 had a similar clinical outcome and prognosis to that of non-HIV patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827165     DOI: 10.1097/QAD.0b013e32833e508f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

1.  Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Authors:  Chiara Agrati; Cristiana Gioia; Concetta Castilletti; Daniele Lapa; Giulia Berno; Vincenzo Puro; Fabrizio Carletti; Eleonora Cimini; Carla Nisii; Flora Castellino; Federico Martini; Maria R Capobianchi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

2.  Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.

Authors:  Nancy F Crum-Cianflone; Erik Iverson; Gabriel Defang; Patrick J Blair; Lynn E Eberly; Jason Maguire; Anuradha Ganesan; Dennis Faix; Christopher Duplessis; Tahaniyat Lalani; Timothy Whitman; Carolyn Brandt; Grace Macalino; Eugene V Millar; Timothy Burgess
Journal:  Vaccine       Date:  2011-03-01       Impact factor: 3.641

Review 3.  Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic.

Authors:  Anandi N Sheth; Pragna Patel; Philip J Peters
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

4.  The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.

Authors:  Bohdan Nosyk; Behnam Sharif; Huiying Sun; Curtis Cooper; Aslam H Anis
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

5.  Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients.

Authors:  Ignacio Martin-Loeches; Emili Díaz; Loreto Vidaur; Antoni Torres; Cesar Laborda; Rosa Granada; Juan Bonastre; Mar Martín; Josu Insausti; Angel Arenzana; Jose Eugenio Guerrero; Ines Navarrete; Jesus Bermejo-Martin; David Suarez; Alejandro Rodriguez
Journal:  Crit Care       Date:  2011-11-28       Impact factor: 9.097

6.  Pandemic (H1N1) 2009 and HIV Infection.

Authors:  Shireesha Dhanireddy; Robert D Harrington; Heidi M Crane; Matthew R Gingo; Alison Morris; Laurence Huang; Kristina Crothers
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

7.  An analysis of 332 fatalities infected with pandemic 2009 influenza A (H1N1) in Argentina.

Authors:  Ana M Balanzat; Christian Hertlein; Carlos Apezteguia; Pablo Bonvehi; Luis Cámera; Angela Gentile; Oscar Rizzo; Manuel Gómez-Carrillo; Fatima Coronado; Eduardo Azziz-Baumgartner; Pollyanna R Chávez; Marc-Alain Widdowson
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

8.  Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.

Authors:  Claire-Anne Siegrist; Christian van Delden; Michael Bel; Christophe Combescure; Cécile Delhumeau; Matthias Cavassini; Olivier Clerc; Sara Meier; Karine Hadaya; Paola M Soccal; Sabine Yerly; Laurent Kaiser; Bernard Hirschel; Alexandra Calmy
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  Seroepidemiologic effects of influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore.

Authors:  James M Trauer; Don Bandaranayake; Robert Booy; Mark I Chen; Michelle Cretikos; Gary K Dowse; Dominic E Dwyer; Michael E Greenberg; Q Sue Huang; Gulam Khandaker; Jen Kok; Karen L Laurie; Vernon J Lee; Jodie McVernon; Scott Walter; Peter G Markey
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

10.  HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.

Authors:  Timothy R Leahy; Michelle Goode; Paul Lynam; Patrick J Gavin; Karina M Butler
Journal:  Influenza Other Respir Viruses       Date:  2014-02-18       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.